Abstract：
OBJECTIVE: Posterior capsular opacification is treated using neodymium-doped yttrium aluminium garnet laser capsulotomy that leads to increased intraocular pressure. Here, we compare the effects of dorzolamide hydrochloride + timolol maleate versus brimonidine on intraocular pressure. We also investigate their side effects after neodymium-doped yttrium aluminium garnet laser capsulotomy. In these patients, there are no prior studies comparing the results of these two drugs.
METHODS: Ninety patients with posterior capsule opacification contributed to the study. They received yttrium aluminium garnet laser capsulotomy. After yttrium aluminium garnet laser capsulotomy, they were randomized into three groups. Group 1 received dorzolamide hydrochloride + timolol maleate; Group 2 took brimonidine; and Group 3, the control group, took no drug. Group 1 took dorzolamide hydrochloride + timolol maleate eye drops 1 h before the procedure and on the third hour of the first day and two times per day between the second and the seventh days. Group 2 took brimonidine eye drops 1 h before the procedure and on the third hour of the first day, two times per day between the second and the seventh days.
RESULTS: Brimonidine had a similar side effect profile to the fix combination. Intraocular pressure on the first (p = 0.87) and third days (p = 0.124) were similar in Group 1 (dorzolamide hydrochloride + timolol maleate), Group 2 (brimonidine) and the control group. The mean intraocular pressure value of the control group was significantly higher than Groups 1 and 2 because the anti-glaucomatous effects of the drugs become prominent on the seventh day (p = 0.041). In Group 1 and Group 2, intraocular pressure was significantly lower than the control group on the seventh day (p = 0.041). Stinging, itching, hyperemia and Tyndall rates were similar in Group 1, Group 2 and the control group. Watery eyes were less common in the brimonidine group than in the dorzolamide hydrochloride-timolol maleate and the control groups on the seventh day (p = 0.02). Brimonidine also significantly lowered the chemosis rate on the third (p = 0.04) and seventh (p = 0.03) days.
CONCLUSIONS: We suggest that brimonidine and a combination of dorzolamide + timolol are similarly effective at reducing eye pressure for routine cases. In cases where intraocular pressure attacks might be at higher risk, using the dorzolamide + timolol combination would be more appropriate.
METHODS: Ninety patients with posterior capsule opacification contributed to the study. They received yttrium aluminium garnet laser capsulotomy. After yttrium aluminium garnet laser capsulotomy, they were randomized into three groups. Group 1 received dorzolamide hydrochloride + timolol maleate; Group 2 took brimonidine; and Group 3, the control group, took no drug. Group 1 took dorzolamide hydrochloride + timolol maleate eye drops 1 h before the procedure and on the third hour of the first day and two times per day between the second and the seventh days. Group 2 took brimonidine eye drops 1 h before the procedure and on the third hour of the first day, two times per day between the second and the seventh days.
RESULTS: Brimonidine had a similar side effect profile to the fix combination. Intraocular pressure on the first (p = 0.87) and third days (p = 0.124) were similar in Group 1 (dorzolamide hydrochloride + timolol maleate), Group 2 (brimonidine) and the control group. The mean intraocular pressure value of the control group was significantly higher than Groups 1 and 2 because the anti-glaucomatous effects of the drugs become prominent on the seventh day (p = 0.041). In Group 1 and Group 2, intraocular pressure was significantly lower than the control group on the seventh day (p = 0.041). Stinging, itching, hyperemia and Tyndall rates were similar in Group 1, Group 2 and the control group. Watery eyes were less common in the brimonidine group than in the dorzolamide hydrochloride-timolol maleate and the control groups on the seventh day (p = 0.02). Brimonidine also significantly lowered the chemosis rate on the third (p = 0.04) and seventh (p = 0.03) days.
CONCLUSIONS: We suggest that brimonidine and a combination of dorzolamide + timolol are similarly effective at reducing eye pressure for routine cases. In cases where intraocular pressure attacks might be at higher risk, using the dorzolamide + timolol combination would be more appropriate.
摘要：
目的：使用掺钕钇铝石榴石激光囊切开术治疗后囊膜混浊，导致眼压升高。这里,我们比较了盐酸多佐胺+马来酸噻吗洛尔与溴莫尼定对眼压的影响。我们还研究了掺钕钇铝石榴石激光囊切开术后的副作用。在这些患者中,以前没有研究比较这两种药物的结果。
方法：90例后囊混浊患者参与了这项研究。他们接受了钇铝石榴石激光囊切开术。钇铝石榴石激光囊切开术后，他们被随机分为三组.第1组接受盐酸多佐胺+马来酸噻吗洛尔；第2组服用溴莫尼定；第3组，对照组，没有服用任何药物。第1组在手术前1小时和第一天的第三个小时服用盐酸多佐胺+马来酸噻吗洛尔滴眼液，第二天和第七天之间每天两次。第2组在手术前1小时和第一天的第三个小时服用溴莫尼定滴眼液，在第二天和第七天之间每天两次。
结果：溴莫尼定具有与固定组合相似的副作用。第1组（盐酸多佐胺+马来酸噻吗洛尔）第1天（p=0.87）和第3天（p=0.124）的眼压相似，第2组(溴莫尼定)和对照组。对照组的平均眼压值显著高于第1组和第2组,因为药物的抗青光眼作用在第7天变得突出(p=0.041)。在第1组和第2组中，第7天的眼压明显低于对照组（p=0.041）。刺痛,瘙痒,第1组、第2组及对照组的充血率和耳痛率相似。在第7天，溴莫尼定组的水眼要比盐酸多佐胺-马来酸噻吗洛尔和对照组少（p=0.02）。溴莫尼定在第3天（p=0.04）和第7天（p=0.03）也显着降低了化学生成率。
结论：我们建议溴莫尼定和多佐胺+噻吗洛尔的组合在降低常规病例的眼压方面同样有效。如果眼内压发作的风险更高，使用多佐胺+噻吗洛尔组合将是更合适的。
方法：90例后囊混浊患者参与了这项研究。他们接受了钇铝石榴石激光囊切开术。钇铝石榴石激光囊切开术后，他们被随机分为三组.第1组接受盐酸多佐胺+马来酸噻吗洛尔；第2组服用溴莫尼定；第3组，对照组，没有服用任何药物。第1组在手术前1小时和第一天的第三个小时服用盐酸多佐胺+马来酸噻吗洛尔滴眼液，第二天和第七天之间每天两次。第2组在手术前1小时和第一天的第三个小时服用溴莫尼定滴眼液，在第二天和第七天之间每天两次。
结果：溴莫尼定具有与固定组合相似的副作用。第1组（盐酸多佐胺+马来酸噻吗洛尔）第1天（p=0.87）和第3天（p=0.124）的眼压相似，第2组(溴莫尼定)和对照组。对照组的平均眼压值显著高于第1组和第2组,因为药物的抗青光眼作用在第7天变得突出(p=0.041)。在第1组和第2组中，第7天的眼压明显低于对照组（p=0.041）。刺痛,瘙痒,第1组、第2组及对照组的充血率和耳痛率相似。在第7天，溴莫尼定组的水眼要比盐酸多佐胺-马来酸噻吗洛尔和对照组少（p=0.02）。溴莫尼定在第3天（p=0.04）和第7天（p=0.03）也显着降低了化学生成率。
结论：我们建议溴莫尼定和多佐胺+噻吗洛尔的组合在降低常规病例的眼压方面同样有效。如果眼内压发作的风险更高，使用多佐胺+噻吗洛尔组合将是更合适的。
